US FDA consults on draft standards for clinical trial imaging endpoints
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is seeking feedback on a draft guideline designed to help sponsors in the use of imaging endpoints in clinical trials of therapeutic drugs and biologic products1,2.